Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.47 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MC4R | P32245 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27675306 | 1.00 | SIGMAR1 (0.54) | SIGMAR1GAAMEN1KMT2ATSHR | |
| SCHEMBL10755612 | 0.91 | MEN1 (0.50) | SIGMAR1GAAMEN1KMT2ATSHR | |
| SCHEMBL9233103 | 0.85 | POLB (0.58) | SIGMAR1GAAMEN1KMT2APOLB | |
| SCHEMBL14626231 | 0.84 | SIGMAR1 (0.54) | SIGMAR1GAAMEN1KMT2ATSHR | |
| SCHEMBL28911881 | 0.83 | ALDH1A1 (0.68) | GAAMEN1KMT2APOLBALDH1A1 | |
| SCHEMBL19463296 | 0.81 | GAA (0.59) | SIGMAR1GAAMEN1KMT2ATSHR | |
| SCHEMBL19463297 | 0.81 | GAA (0.59) | SIGMAR1GAAMEN1KMT2ATSHR | |
| SCHEMBL18123311 | 0.81 | POLB (0.65) | SIGMAR1GAAMEN1KMT2ATSHR | |
| SCHEMBL19779269 | 0.80 | POLB (0.55) | GAAMEN1KMT2ATSHRPOLB | |
| SCHEMBL28119006 | 0.80 | GAA (0.58) | SIGMAR1GAAMEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4812581-A | PREPARING AZETIDINE-3-CABOXYLIC ACID | SHELL OIL COMPANY (US) | 1989-03-14 | — | — | US | claimed |
| EP-0221579-A1 | A process for the preparation of an azetidine-3-carboxylic acid or salt thereof | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1987-05-13 | — | — | EP | claimed |
| US-20250340560-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BEIGENE SWITZERLAND GMBH (CH) | 2025-11-06 | — | — | US | disclosed |
| US-20240254128-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BEIGENE SWITZERLAND GMBH (CH) | 2024-08-01 | — | — | US | disclosed |
| US-20230013862-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BEIGENE SWITZERLAND GMBH (CH) | 2023-01-19 | — | — | US | disclosed |
| US-20230013862-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BEIGENE SWITZERLAND GMBH (CH) | 2023-01-19 | — | — | US | disclosed |
| US-11142528-B2 | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators | BEIGENE SWITZERLAND GMBH (CH) | 2021-10-12 | — | — | US | disclosed |
| US-11142528-B2 | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators | BEIGENE SWITZERLAND GMBH (CH) | 2021-10-12 | — | — | US | disclosed |
| US-20200148690-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BEONE MEDICINES I GMBH (CH) | 2020-05-14 | — | — | US | disclosed |
| US-20200148690-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BEONE MEDICINES I GMBH (CH) | 2020-05-14 | — | — | US | disclosed |
| US-10570139-B2 | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators | BEIGENE SWITZERLAND GMBH (CH) | 2020-02-25 | — | — | US | disclosed |
| US-4778577-A | OXIDATION OF ALCOHOL TO ACID WITH NICKEL/III/COMPOUND | SHELL OIL COMPANY (US) | 1988-10-18 | — | — | US | disclosed |
| EP-0165636-B1 | PROCESS FOR PREPARING AZETIDINE DERIVATIVES AND INTERMEDIATES THEREIN | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1988-08-10 | — | — | EP | disclosed |
| US-4701534-A | INTERMEDIATE | SHELL OIL COMPANY (US) | 1987-10-20 | — | — | US | disclosed |
| EP-0221579-A1 | A process for the preparation of an azetidine-3-carboxylic acid or salt thereof | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1987-05-13 | — | — | EP | disclosed |
| US-4665197-A | NITRIC ACID OXIDATION OF 3,3-BIS/HYDROXYMETHYL/AZETIDINE/ | SHELL OIL COMPANY (US) | 1987-05-12 | — | — | US | disclosed |
| EP-0201957-A2 | Process for the preparation of a carboxylic acid salt | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1986-11-20 | — | — | EP | disclosed |
| EP-0199413-A2 | Process for preparing azetidine derivatives and novel intermediates therein | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1986-10-29 | — | — | EP | disclosed |
| EP-0168852-A1 | Azetidine derivatives and their preparation | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1986-01-22 | — | — | EP | disclosed |
| EP-0165636-A1 | Process for preparing azetidine derivatives and intermediates therein | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1985-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240254128-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BTK, LCK, SYK | SIGMAR1 3653/4885GAA 2740/4885MEN1 3923/4885 |
| US-10570139-B2 | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators | BTK, LCK, SYK | SIGMAR1 3653/4885GAA 2740/4885MEN1 3923/4885 |
| US-20200148690-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BTK, LCK, SYK | SIGMAR1 3653/4885GAA 2740/4885MEN1 3923/4885 |
| US-11142528-B2 | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators | BTK, LCK, SYK | SIGMAR1 3653/4885GAA 2740/4885MEN1 3923/4885 |
| US-20230013862-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BTK, LCK, SYK | SIGMAR1 3653/4885GAA 2740/4885MEN1 3923/4885 |
| US-20250340560-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BTK, LCK, SYK | SIGMAR1 3653/4885GAA 2740/4885MEN1 3923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.